{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT03207243: Phase 2 Interventional Completed Asthma
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:zirconium (⁸⁹Zr) crefmirlimab berdoxam [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00087022: Phase 3 Interventional Completed Kidney Cancer
(2004)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01802814: Phase 3 Interventional Completed Acute Lymphoblastic Leukemia (ALL)
(2014)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02383810: Phase 2 Interventional Completed Drug and/or Toxin-induced Diarrhea
(2015)
Source URL:
Class:
PROTEIN
Elsiglutide (ZP 1846) is a synthetic 39-amino acid glucagon-like peptide-2 (GLP-2) analogue. Upon subcutaneous administration, elsiglutide binds to GLP-2 receptors and thereby promotes proliferation of epithelial cells. Elsiglutide prevents or reduces the occurrence of gastrointestinal damage caused by chemotherapeutic agents, including gastrointestinal mucositis and chemotherapy-induced diarrhea (CID). Elsiglutide is being developed by Helsinn Healthcare, for the prevention of chemotherapy-induced diarrhoea.
Status:
Investigational
Source:
NCT03371251: Phase 1/Phase 2 Interventional Completed Systemic Lupus Erythematosus
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:grisnilimab setaritox [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:exlinkibart [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:davoceticept [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:trontinemab [INN]
Source URL:
Class:
PROTEIN
